Functional Analysis of Familial Asp67Glu and Thr1051Ser BRCA1 Mutations in Breast/Ovarian Carcinogenesis by Pongsavee, Malinee et al.
Int. J. Mol. Sci. 2009, 10, 4187-4197; doi:10.3390/ijms10094187 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
 
Functional Analysis of Familial Asp67Glu and Thr1051Ser 
BRCA1 Mutations in Breast/Ovarian Carcinogenesis 
 
Malinee Pongsavee 
1,*, Pimpicha Patmasiriwat 
2 and Grady F. Saunders 
3,† 
 
1  Department of Medical Technology, Faculty of Allied Health Sciences, Thammasat University, 
Rangsit Campus, Pathumthani, Thailand 
2  Department of Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Salaya 
Campus, Nakornpathom, Thailand; E-Mail: mtppm@mahidol.ac.th (P.P.) 
3  Department of Biochemistry and Molecular Biology, The University of Texas M.D. Anderson 
Cancer Center, Houston, TX 77030, USA 
 
*  Author to whom correspondence should be addressed; E-Mail: malineep@tu.ac.th;  
Tel. +66-2-9869213 (Ext. 7252); Fax: +66-2-5165379. 
 
†  Deceased 26 August 2005. 
 
Received: 21 August 2009 / Accepted: 21 September 2009 / Published: 24 September 2009 
 
 
Abstract: Estrogen is believed to be pre-initiator in the risk of breast cancer. The BRCA1 
is a tumor suppressor gene associated with breast and ovarian cancer risk. This report 
describes functional analysis of two BRCA1 missense mutations (Asp67Glu and 
Thr1051Ser) observed in the familial breast/ovarian cancer patients in Thailand. Levels of 
luciferase activity of the two mutations were relatively lower than in the wild-type BRCA1. 
It is indicated that mutants may fail to promote the estrogen receptor dependent functions. 
It is presumed that estrogen and insulin/IGF-1 regulate c-Myc and cyclin D1 during breast 
cancer cell proliferation. It is also likely to affect ubiquitination mechanism. Since three 
affected cancer families carry the Asp67Glu mutation, it is believed that this type of 
mutation could have some effect on breast/ovarian cancer progression. 
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1. Introduction 
 
Breast cancer is the most common form cancer of women worldwide. In many developing 
countries, including in Asia, which were formerly believed to have low risk of breast cancer, the 
incidence is presently increasing. BRCA1 and BRCA2 are the two tumor suppressor genes associated 
with breast and ovarian cancer risk [1]. BRCA1 was localized on chromosome 17q21. The gene spans 
approximately 100 kb of genome, containing 22 coding and 2 noncoding exons. Its transcriptional  
7.8 kb mRNA product encodes a 200 kD nuclear phosphoprotein consisting of 1,863 amino acids [2]. 
The N-terminus of BRCA1 contains a ring finger motif which is a cysteine and histidine rich (C3HC4) 
and domain capable of zinc binding. This zinc–binding ring finger domain is located close to the 
amino-terminus (residues 20-68) [2]
 and has ubiquitin ligase activity [3-4]. The C-terminal region of 
BRCA1 contains two carboxyl-terminal domains (BRCT domains). The BRCT domain is a 
phosphoprotein binding domain. BRCT domains interact with multiple transcription activators and co-
repressors. The BRCT domain can interact with p53 and stimulates p53-dependent transcription of the 
p21 promoter. BRCA1 C-terminus interacts with RNA polymerase III holoenzyme in order to function 
as a transcriptional activator [5]. BRCT domain also has a role in the response to DNA damage [6]. 
The biological functions of BRCA1 are the maintenance of genome stability and DNA repair. The 
other two functions are transcriptional activity and growth and differentiation [3-6]. BRCA1 is 
expressed in a number of tissues including breast and ovary and abundant in testis and thymus. 
Estrogen plays important roles in the growth and differentiation of female secondary sex 
characteristics, in reproduction and in cellular metabolism [7,8]. The hormone may serve as the pre-
initiator and can alter the morphology of the mammary gland [9]. Once breast cancer initiation takes 
place, estrogen might promote the growth of transformed cells and lead to the development of breast 
cancer [10]. In addition, estrogen also increases proliferation and genetic instability by inducing free 
radical-mediated DNA damage and mutation [11]. 
Estrogens mediate their activity by interaction and activation of estrogen receptors (ER) [8]. Two 
forms of estrogen receptor, ER α and ER β are members of a nuclear receptor superfamily which 
responses to a variety of hydrophobic ligands such as steroid hormones (estrogens, glucocorticoids 
etc.), retinoic acid (vitamin A), vitamin D etc. [8]. Human ER α comprises of 595 amino acids and has 
molecular weight of 66-70 kD. It contains six functional domains (A to F). The A/B region contains 
activation function 1 (AF-1) which is important for transactivation and gene specificity. Region C is 
DNA binding domain (DBD) and contains two zinc finger motif and responsible for the binding of the 
receptor to estrogen response elements as well as contribute to dimerization and transactivation. 
Region D is the hinge region and contain nuclear localization. Region E contains the ligand binding 
domain (LBD) and activation function 2 (AF-2). AF-2 involves in transactivation in cooperation with 
AF-1. Human estrogen receptor β has 477 amino acids and is expressed in many tissues, including 
immune system and urogenital tract [12].  
Upon hormone binding, the receptor undergoes physiochemical changes including phosphorylation 
at specific serine and tyrosine residues that are accompanied by conformational changes [12]. The 
transformed ER dimer binds to its specific estrogen response element (ERE) located in the promoter 
region of estrogen responsive genes, regulating their transcriptional activity. ER-ERE interactions are 
augmented by the binding of co-activators or co-repressors that further regulate gene   Int. J. Mol. Sci. 2009, 10                 
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transcription [13]. BRCA1 is a protein known to interact with and regulate activity of estrogen 
receptor α [14] as well as androgen receptor [15].  
In Thailand, mutations in the BRCA1 and BRCA2 exons were found in cases of Thai familial 
breast/ovarian cancer, or isolated early-onset cancer. Asp67Glu and Thr1051Ser are the two BRCA1 
missense mutations which occurred in Thai familial breast/ovarian cancer patients [16]. The 
significance of these two mutations are unknown. Estrogen receptor signaling pathway is one of the 
pathways involved in breast/ovarian carcinogenesis. We studied the role of these two missense 
mutations in estrogen receptor signaling pathway for promote the breast/ovarian carcinogenesis.  
 
2. Results and Discussion 
 
The report of Patmasiriwat et al. [16] showed that Asp67Glu and Thr1051Ser BRCA1 missense 
mutations appeared in some of familial breast/ovarian cancer. Figure 1 and 2 showed the pedigree of 
the familial breast/ovarian cancer families which were found these two missense mutations. This 
report also showed that the patient in family F17 (ID34), the patient in family F18 (ID35) and one 
isolated early-onset breast cancer case (ID36) had Asp67Glu BRCA1 mutation at exon 5. For the 
patient ID34 in family F17, the age of onset was low (27 years) and she had infiltrative 
adenocarcinoma of right breast. Both breast and ovarian cancer were found among the F17 members 
(Figure 1). Only breast cancer was found among the two members in family F18. Age of onset for the 
isolated breast cancer case (ID36) was 25 years. 
 
Figure 1. Pedigree of the breast cancer patient in F17. The patient had Asp67Glu BRCA1 
missense mutation. 
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The patient ID27 in family F15 carried BRCA1 3300delA-ter1061 at exon 11 and also had 
Thr1051Ser [16]. The age of onset was 42 years and she had bilateral ovarian serous papillary 
carcinoma. The clinical pathology showed that the estrogen receptor and progesterone receptor were 
positive in this case. The three members in F15 were ovarian cancer patients (Figure 2). 
 
Figure 2. Pedigree of the ovarian cancer patient in F15. The patient had BRCA1 
Thr1051Ser missense mutation in addition to 3300delA frameshift mutation. Estrogen 
receptor and progesterone receptor were positive in this patient.  
 
 
The role of Asp67Glu and Thr1051Ser on estrogen receptor signaling pathway were studied by 
transient transfection in DU145 cell line (prostate cancer cell line) [14] and luciferase activity was 
analysed. The first, second and sixth well were the proper control wells. Comparing luciferease 
activity of the six wells in this experiment, it showed that activity of the second well was the highest. 
The construct vectors of the second well include ER vector, ERE vector and estrogen, all components 
are necessary for estrogen receptor signaling. The first well had no estrogen and the sixth well had no 
ER vector. The luciferase activity of the first well was higher than the sixth well. From Figure 3, the 
average luciferase activity of the mutants (the fourth well and the fifth well) was significantly different 
from the wild-type BRCA1 (the third well) (P < 0.05). Luciferase activity levels of the two BRCA1 
missense mutations were relatively lower than the wild-type BRCA1 (the third well). Estrogen receptor 
signaling pathway was inhibited in the presence of wild-type BRCA1 in DU145 transfected cells as in 
the two mutants. In the vector construction in which ERE element was ligated to luciferase gene, level 
of lucifersase activity as response to ER in the presence of both BRCA1 and estrogen was lower than 
the activity in system without BRCA1. Thus, our work showed that the two BRCA1 missense mutations 
failed to promote the estrogen receptor signaling pathway in breast/ovarian carcinogenesis. 
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Figure 3. The role of BRCA1 missense mutation, Asp67Glu and Thr1051Serine, to 
estrogen receptor signaling pathway. Wt.BRCA1 expression vector and mutant BRCA1 
expression vectors were transfected into DU145 cell line for 48 hrs. Cells were stimulated 
by estrogen and assay for pERE-Elb-Luc reporter activity. The luciferase activity of 
BRCA1 mutants were different from activity of the wild-type (P < 0.05). These missense 
mutations failed to promote the estrogen receptor signaling pathway for breast/ovarian 
carcinogenesis.  
 
pcDNA3   +  +  -  -  -  + 
ER +  +  +  +  +  - 
ERE +  +  +  +  +  + 
Estrogen -  +  +  +  +  + 
wt.BRCA1  - - + -  - - 
BRCA1 Asp67Glu  -  -  -  +  -  - 
BRCA1 Thr1051Ser  -  -  -  -  +  - 
 
In Thailand, the missense mutations Asp67Glu and Thr1051Ser of BRCA1 were previously detected 
in familial breast/ovarian cancer patients or isolated early onset cases. Asp67Glu missense mutation 
was occurred in three Thai breast/ovarian cancer patients. 3300delA-ter1061 frameshift mutation 
occurred in the other three Thai breast/ovarian cancer patients and two out of three patients had both 
Thr1051Ser missense mutation and 3300delA-ter1061 frameshift mutation occurred in the same 
person [16].  
Estrogen is important for the development of female reproductive tissues, particularly the uterus 
and mammary glands [17] and plays a central role in the development and progression of human breast 
cancer [18]. The mechanism which estrogen stimulate cell proliferation is controversial. Couse et al. 
showed that it could activate estrogen receptor (ER) transcriptional activity while other investigators 
reported the non-transcriptional mechanisms by activation of intracellular signaling such as the 
pathway involving MAPK [19-20]. Estrogen induces mitogenic effects in breast epithelial cells by 
stimulating G0/G1 resting cells to enter the cell cycle and progress through the G1-S transition to 
complete a round of cell division [21-22].  Int. J. Mol. Sci. 2009, 10                 
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Estrogen receptor (ER) is a candidate locus for familial late onset breast cancer susceptibility [14]. 
The high expression of ER in breast cancer is associated with responsiveness to hormonal treatment 
and a favorable prognosis. Mutation in the ER may modify the hormonal response in breast epithelium 
and potentially result in inherited susceptibility to breast cancer [23].  
Estrogen binds and activates cytoplasmic ER α, which translocates to the nucleus, dimerizes, binds 
to estrogen responsive enhancer elements (EREs) on the target genes and activates transcription. Wild-
type BRCA1 protein suppress estrogen-dependent mammary epithelial proliferation by inhibiting ER 
α–mediated transcriptional pathways related to cell proliferation [14]. The inhibition of estrogenic 
stimulation for mammary epithelial cell growth by BRCA1 contributes to breast cancer suppression. 
BRCA1 function involves in estrogen receptor signaling pathway. Our study is in agreement with Fan 
et al. who showed that the wild-type BRCA1 inhibits estrogen receptor signaling pathway and may 
suppress estrogen-dependent mammary epithelial proliferation [14]. The loss of this inhibitory activity 
is believed to promote the proliferation of genetically damaged mammary epithelial cells. As proposed 
by Fan et al. and Zheng et al. [14,24], an inactivation of the ability to repress ER α transcriptional 
activity by BRCA1 mutation may contribute mammary carcinogenesis.  
Cyclin D1 is another factor which has been reported to involve in estrogen receptor function. Cyclin 
D1 protein is overexpressed in 25-80% of invasive ductal carcinoma cases. The protein is associated 
with poor prognosis in estrogen receptor α-positive cases [25]. Cyclin D1 is a downstream mediator of 
estrogen in MCF-7 cells [26,27]. Cyclin D1 also represents one of the key cell cycle regulators which 
is downstream of the PI3-kinase pathway and is required in addition to c-Myc to mediate the 
mitogenic effects of estrogen and insulin [28].  
Studying about the role of two missense mutations in BRCA1 (Asp67Glu, Thr1051Ser) to estrogen 
receptor signaling was investigated. Result showed that estrogen receptor signaling pathway was 
inhibited in the presence of BRCA1 expression vector in DU145 cells. In the construct which ERE 
element ligated to luciferase gene, level of luciferase activity as response to ER in the presence of both 
estrogen and BRCA1 was lower than the activity in system without BRCA1. Luciferase activity levels 
in the presence of the two expression vectors were also low, similar to the wild-type BRCA1. Thus the 
two  BRCA1 missense mutations could not promote the estrogen receptor signaling pathway for 
familial breast/ovarian carcinogenesis. These mutations may involve in familial breast/ovarian 
carcinogenesis in the other pathways. Breast/ovarian cancer might be occurred because of the other 
factors such as c-Myc, cyclins, insulin-like growth factor-I (IGF-I) etc. Estrogen and IGF-1 regulate c-
Myc and cyclin D1 to stimulate breast cancer cell proliferation [28]. IGF-1 induces cyclin D1 and 
stabilizes the level of c-Myc and cyclin D1 through the PI3-kinase pathways. Estrogen activates the 
PI3-kinase and MAPK pathways by stimulating the autocrine growth factors. Cyclin D1 activates 
CDK4/6 while c-Myc induces the activation of cyclin E/CDK2 to stimulate maximal G1-S phase cell 
cycle progression [26,28-30]. These two missense mutations might promote estrogen and   
insulin/IGF-1 functions which regulate c-Myc and cyclin D1 for stimulate breast cancer cell 
proliferation.  
The other pathway which these two missense mutations may involve in carcinogenesis is 
ubiquitination. The ring domains of BRCA1 (residues 1-109) are associated with BARD1 [4]
 and 
BAP1 [3]. BAP1 (BRCA1-associated protein) is a member of the ubiquitin C-terminal hydrolase 
(UCH) family and can bind BRCA1. UCH degrades ubiquitin. BRCA1 is also a ring finger protein that Int. J. Mol. Sci. 2009, 10                 
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harbors E3 ubiquitin ligase activity and it is a part of an ubiquitin ligase complex [31,32]. The 
ubiquitin-proteosome pathway involves in regulating the stability of ring finger-containing proteins 
[3].  In vitro, the BRCA1 ubiquitin ligase activity requires interaction with two proteins. The   
N-terminus of BRCA1 interacts with BARD1 to form a heterodimer. The heterodimer has substantial 
E3 ubiquitin ligase activity with the UbcH5a class of E2 ubiquitin conjugating enzymes [33,34]. Loss 
of the activity occurs in some forms of BRCA1-mediated cancer, as disease-associated mutations that 
substitute Zn
2+
-binding residues within the BRCA1 ring affects BRCA1 ubiquitin ligase activity. This 
zinc–binding ring finger domain is located close to the amino-terminus (residues 20-68) [2]
 and 
Asp67Glu missense mutation is occurred in the amino-terminus. The missense mutation that 
predisposed to breast cancer cluster in the Zn
2+
- binding residues of the BRCA1 ring finger domain is 
critical to the ubiquitin ligase function [35-37] and the BRCA1 ubiquitin ligase function is linked to 
the DNA damage repair role of BRCA1 [38]. 
 
3. Experimental Section  
 
3.1. Construction of vectors  
 
The BRCA1 Asp67Glu and Thr1051Ser expression vectors were created from wild-type BRCA1 
expression vector by using site directed mutagenesis kit (Strategene, Wilmington, DE, USA). The 
mutagenic primers for Asp67Glu BRCA1 expression vector was forward: 5´-GT CCT TTA TGT AAG 
AAT GAG ATA ACC AAA AGG AGC C-3´ and reverse: 5´-G GCT CCT TTT GGT TAT CTC ATT 
CTT ACA TAA AGG AC-3´. The mutagenic primers for Thr1051Ser BRCA1 expression vector was 
forward: 5´-GAA GTA GGT TCC AGT AGT AAT GAA GTG GGC TCC AG-3´ and reverse:   
5´-CT GGA GCC CAC TTC ATT ACT ACT GGA ACC TAC TTC-3´. The changed base in each 
missense mutation was underlined in the sequence of each forward primer detailed above. For site 
directed mutagenesis, 5 μL of 10 × reaction buffer, 10 ng of DNA template, 125 ng of forward primer, 
125 ng of reverse primer, 1 μL of dNTP mix, 3 μL of QuickSolution, and ddH2O was added to a final 
volume of 50 μL. Then 1 μL of Pfu Turbo DNA polymerase (2.5 U/μL) was added. The PCR cycle 
was as followed: 1 cycle of 95 °C (1 min); 18 cycles of 95 °C (50 sec), 60 °C (50 sec) and 68 °C  
(1 min/kb of plasmid length); 1 cycle of 68 °C (7 mins). After the PCR cycling, placed the reaction 
tubes on ice for 2 mins. to cool the reaction for 37 °C or below. One μL of Dpn I restriction enzyme 
(10 U/μL.) was added and gently mixed the reaction mixture by up and down pipetting, then incubated 
at 37 °C for 1 hour. Two μL of the Dpn I-treated DNA was added in XL10-Gold ultracompetent cells, 
swirled the transformation reactions gently and incubated on ice for 30 mins. The reaction mixture was 
heat shocked at 42 °C for 30 sec and incubated on ice for 2 mins. The reaction mixture was added in 
LB media, incubated at 37 °C for 1 hour with shaking at 225-250 rpm. After incubation, 50 μL of the 
transformation mixture was plated on LB/ampicillin agar at 37 °C for 16 hours. The white colonies 
were picked up and cultured in LB/ampicillin media. They were incubated at 37 °C for 16 hours with 
shaking at 225-250 rpm, purified by Miniprep kit (Qiagen, Valencia, CA, USA) and sequenced by 
automated DNA sequencing. 
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3.2. Cell line and culture 
 
DU145 (prostate cancer) cell line was used in this assay. DU145 was grown in DMEM/F-12 
medium (Gibco BRL Life Technologies, San Diego, CA., USA) supplemented with 10% fetal calf 
serum and kept in a humidified 37 °C, 5% CO2 incubator. 
 
3.3. Transient transfection 
 
The vectors used in this assay were: (1) wild-type BRCA1 expression vector, (2) Asp67Glu BRCA1 
expression vector, (3) Thr1051Ser BRCA1 expression vector, (4) pERE-Elb-LUC vector as reporter 
gene, (4) RSV-ER expression vector, (5) pcDNA3 vector and (6) pSV40 β-galactosidase vector. 
DU145 cells at 50-70% of confluency in 24 well-cell culture plate were incubated for 24 hours. Six 
wells were used in this assay. Each well contained 10
5 DU145 cells, and various combination of the 
vectors were added to each well as follows: the pERE-Elb-LUC vector, RSV-ER vector, pcDNA3 
vector, pSV40 β-galactosidase vector in the first well; the pERE-Elb-LUC vector, RSV-ER vector, 
pcDNA3 vector, pSV40 β-galactosidase vector in the second well; the pERE-Elb-LUC vector, RSV-
ER vector, wild-type BRCA1 expression vector, pSV40 β-galactosidase vector in the third well; the 
pERE-Elb-LUC vector, RSV-ER vector, Asp67Glu BRCA1 expression vector, pSV40 β-galactosidase 
vector in the fourth well; the pERE-Elb-LUC vector, RSV-ER vector, Thr1051Ser BRCA1 expression 
vector, pSV40 β-galactosidase vector in the fifth well and the pERE-Elb-LUC vector, pcDNA3 vector, 
pSV40 β- galactosidase vector in the sixth well.  
0.5 µg of each vector was used for transfection in serum free DMEM/F-12 containing 
Lipofectamine plus reagent (Invitrogen, Carlsbad, CA, USA) for 24 hours. After 24 hours, 1 µM 
estrogen (preparation by diluted with 2% charcoal stripped fetal bovine serum) was added in the well 
number second to the sixth, and incubated for 24 hours. The pSV40 β-galactosidase vector (Promega 
Corp., Madison, WI, USA) was added as an internal control. An equivalent amount of the pcDNA3 
vector was used as the vector control. After estrogen was added and incubated for 24 hours, the 
transfected cells were washed twice with PBS. Luciferase and β-galactosidase assays were performed 
according to the manufacturer’s instruction. Luciferase activities were normalized in relative to   
β-galactosidase activity.  
 
4. Conclusions 
 
Our study concludes that the two BRCA1 missense mutations failed to promote the estrogen 
receptor signaling pathway in familial breast/ovarian carcinogenesis. They may play as a mild cancer-
risk modifier of some other defective mechanisms in cell cycle or ubiquitination and probably 
cooperate with these mechanisms to induce cancer in the breast/ovarian cancer patients. 
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